Avapro

Product NDC
0024-5851
11-digit product format
000245851
Labeler code
0024
Product ID
0024-5851_b36c9035-33ad-4c8f-b47f-030436e0ef4d
Type
HUMAN PRESCRIPTION DRUG
Nonproprietary name
irbesartan
Dosage form
TABLET, FILM COATED
Route
ORAL
Labeler
Sanofi-Aventis U.S. LLC
Application
NDA020757
Marketing category
NDA
Marketing start
2013-01-01
Substance
IRBESARTAN
Active strength
150 mg/1
Pharmacologic classes
Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC]
NDC exclude flag
No
Listing certified through
2027-12-31
Current FDA listing
Yes

NDC auxiliary status#

These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.

Current NDC status page 1 of 1 · 1 matching rows.

Dataset, Scope, Product NDC table
DatasetScopeProduct NDCPackage NDCCodeStatusReporting periodSource date
excluded packagepackage0024-58510024-5851-90DDiscontinued by firm2026-08-07

Observed NDC auxiliary status history#

This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.

Historic NDC status page 1 of 1 · 12 matching rows.

View current auxiliary records. · View the auxiliary file history.

Captured / source date, Snapshot, Source SHA-256 table
Captured / source dateSnapshotSource SHA-256
2025-12-14 17:58 UTC · source 2025-12-05d630ba8d3edf…732f749b63fb…
2025-08-27 00:01 UTC · source 2025-08-26f5e01cc5f278…a2eaf40c39c3…
2025-04-01 02:39 UTC · source 2025-03-312ef7874e63bc…57b86245f4fa…
2025-03-28 20:22 UTC · source 2025-03-28a1b67e2a42f9…c4cf2c586c0d…
2025-03-22 03:12 UTC · source 2025-03-21cfe11265f3b6…090c488252e2…
2025-03-10 12:48 UTC · source 2025-03-10cdf11ea48f46…ba0047e9e063…
2025-02-02 03:52 UTC · source 2025-01-31302b2466d912…e7b80fea0513…
2025-01-20 13:05 UTC · source 2025-01-20ed331223b511…672a5bd82f5f…
2025-01-11 03:41 UTC · source 2025-01-100efc9e666f02…f202fb6c5f17…
2024-11-09 02:27 UTC · source 2024-11-08ad56d346431e…cc804d4bbf1e…
2024-10-04 04:10 UTC · source 2024-10-03367a005e9d99…383a685ebd0f…
2024-07-10 04:00 UTC · source 2024-07-09557ba5c1ecfa…9c80585c8c6e…

Source provenance: Browse the complete Orange Book source catalog · source snapshot 1.

Orange Book products#

Current product rows page 1 of 1 · 3 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N020757-001AVAPROIRBESARTAN75MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET / ORALRLD1997-09-30
N020757-002AVAPROIRBESARTAN150MGTABLET / ORALABRLD1997-09-30
N020757-003AVAPROIRBESARTAN300MGTABLET / ORALABRLD, RS1997-09-30

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 2 matching rows.

Application-product, TE code table
Application-productTE code
N020757-002AB
N020757-003AB

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 4 · 123 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-02-19 14:30 UTC2026-02N020757-001AVAPRO75MGTABLET / ORALRLD1997-09-30011fe1cb6892…
2026-02-19 14:30 UTC2026-02N020757-002AVAPRO150MGTABLET / ORALABRLD1997-09-30011fe1cb6892…
2026-02-19 14:30 UTC2026-02N020757-003AVAPRO300MGTABLET / ORALABRLD, RS1997-09-30011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N020757-001AVAPRO75MGTABLET / ORALRLD1997-09-3031067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N020757-002AVAPRO150MGTABLET / ORALABRLD1997-09-3031067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N020757-003AVAPRO300MGTABLET / ORALABRLD, RS1997-09-3031067a03dcf5…
2025-08-23 18:47 UTC2025-08N020757-001AVAPRO75MGTABLET / ORALRLD1997-09-306a471c1ec25d…
2025-08-23 18:47 UTC2025-08N020757-002AVAPRO150MGTABLET / ORALABRLD1997-09-306a471c1ec25d…
2025-08-23 18:47 UTC2025-08N020757-003AVAPRO300MGTABLET / ORALABRLD, RS1997-09-306a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N020757-001AVAPRO75MGTABLET / ORALRLD1997-09-30fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N020757-002AVAPRO150MGTABLET / ORALABRLD1997-09-30fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N020757-003AVAPRO300MGTABLET / ORALABRLD, RS1997-09-30fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N020757-001AVAPRO75MGTABLET / ORALRLD1997-09-30b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N020757-002AVAPRO150MGTABLET / ORALABRLD1997-09-30b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N020757-003AVAPRO300MGTABLET / ORALABRLD, RS1997-09-30b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N020757-001AVAPRO75MGTABLET / ORALRLD1997-09-3003ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N020757-002AVAPRO150MGTABLET / ORALABRLD1997-09-3003ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N020757-003AVAPRO300MGTABLET / ORALABRLD, RS1997-09-3003ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N020757-001AVAPRO75MGTABLET / ORALRLD1997-09-302680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N020757-002AVAPRO150MGTABLET / ORALABRLD1997-09-302680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N020757-003AVAPRO300MGTABLET / ORALABRLD, RS1997-09-302680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N020757-001AVAPRO75MGTABLET / ORALRLD1997-09-305bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N020757-002AVAPRO150MGTABLET / ORALABRLD1997-09-305bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N020757-003AVAPRO300MGTABLET / ORALABRLD, RS1997-09-305bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N020757-001AVAPRO75MGTABLET / ORALRLD1997-09-30d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N020757-002AVAPRO150MGTABLET / ORALABRLD1997-09-30d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N020757-003AVAPRO300MGTABLET / ORALABRLD, RS1997-09-30d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N020757-001AVAPRO75MGTABLET / ORALRLD1997-09-30d06236e962d9…
2024-10-29 15:01 UTC2024-10N020757-002AVAPRO150MGTABLET / ORALABRLD1997-09-30d06236e962d9…
2024-10-29 15:01 UTC2024-10N020757-003AVAPRO300MGTABLET / ORALABRLD, RS1997-09-30d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N020757-001AVAPRO75MGTABLET / ORALRLD1997-09-3079d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N020757-002AVAPRO150MGTABLET / ORALABRLD1997-09-3079d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N020757-003AVAPRO300MGTABLET / ORALABRLD, RS1997-09-3079d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N020757-001AVAPRO75MGTABLET / ORALABRLD1997-09-30301d65b070ca…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N020757-002AVAPRO150MGTABLET / ORALABRLD1997-09-30301d65b070ca…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N020757-003AVAPRO300MGTABLET / ORALABRLD, RS1997-09-30301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N020757-001AVAPRO75MGTABLET / ORALABRLD1997-09-301e350fbaab3a…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N020757-002AVAPRO150MGTABLET / ORALABRLD1997-09-301e350fbaab3a…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N020757-003AVAPRO300MGTABLET / ORALABRLD, RS1997-09-301e350fbaab3a…
2024-05-31 18:47 UTC2024-05N020757-001AVAPRO75MGTABLET / ORALABRLD1997-09-308072bd15b7f6…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 3 · 111 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-02-19 14:30 UTC2026-02N020757-002AB1011fe1cb6892…
2026-02-19 14:30 UTC2026-02N020757-003AB1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N020757-002AB131067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N020757-003AB131067a03dcf5…
2025-08-23 18:47 UTC2025-08N020757-002AB16a471c1ec25d…
2025-08-23 18:47 UTC2025-08N020757-003AB16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N020757-002AB1fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N020757-003AB1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N020757-002AB1b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N020757-003AB1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N020757-002AB103ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N020757-003AB103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N020757-002AB12680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N020757-003AB12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N020757-002AB15bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N020757-003AB15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N020757-002AB1d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N020757-003AB1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N020757-002AB1d06236e962d9…
2024-10-29 15:01 UTC2024-10N020757-003AB1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N020757-002AB179d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N020757-003AB179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N020757-001AB1301d65b070ca…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N020757-002AB1301d65b070ca…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N020757-003AB1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N020757-001AB11e350fbaab3a…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N020757-002AB11e350fbaab3a…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N020757-003AB11e350fbaab3a…
2024-05-31 18:47 UTC2024-05N020757-001AB18072bd15b7f6…
2024-05-31 18:47 UTC2024-05N020757-002AB18072bd15b7f6…
2024-05-31 18:47 UTC2024-05N020757-003AB18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N020757-001AB15c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N020757-002AB15c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N020757-003AB15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N020757-001AB15d02ea3f76ae…
2022-04-08 23:34 UTC2022-04N020757-002AB15d02ea3f76ae…
2022-04-08 23:34 UTC2022-04N020757-003AB15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N020757-001AB14b0b4de00fa7…
2022-04-04 05:41 UTC2022-04N020757-002AB14b0b4de00fa7…
2022-04-04 05:41 UTC2022-04N020757-003AB14b0b4de00fa7…

Additional Listing Data#

Finished product
Yes
Brand name base
Avapro
Listing expiration
2027-12-31

Active Ingredients#

Ingredient, Strength table
IngredientStrength
IRBESARTAN150 mg/1

Harmonized UNII identifiers#

UNII identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
J0E2756Z7NInternal UNII lookup

Harmonized RxCUI identifiers#

RxCUI identifiers page 1 of 1 · 4 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
153666Internal RxNorm lookup
153667Internal RxNorm lookup
200095Internal RxNorm lookup
200096Internal RxNorm lookup

Harmonized SPL set identifiers#

SPL set identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
7885b2a8-be4e-48ab-8113-4e6ab791eb98Available on FDA.report

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
34942a29-de4f-d63c-7755-ba18fe1411a0Product name620180619
a7349398-661d-d9fc-46df-7e128bbd61d9Product name520171113
e0eeb018-194e-4b70-a57d-bac47a97b8eaProduct name120160825

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Related label table
NDCEffectiveRelated label
0024-5851-302024-08-20These highlights do not include all the information needed to use AVAPRO safely and effectively. See full prescribing information for AVAPRO. AVAPRO ® (irbesartan) tablets, for oral use Initial U.S. Approval: 1997
0024-5851-302024-08-20These highlights do not include all the information needed to use AVAPRO safely and effectively. See full prescribing information for AVAPRO. AVAPRO ® (irbesartan) tablets, for oral use Initial U.S. Approval: 1997
0024-5851-302024-08-20These highlights do not include all the information needed to use AVAPRO safely and effectively. See full prescribing information for AVAPRO. AVAPRO ® (irbesartan) tablets, for oral use Initial U.S. Approval: 1997
0024-5851-902024-08-20These highlights do not include all the information needed to use AVAPRO safely and effectively. See full prescribing information for AVAPRO. AVAPRO ® (irbesartan) tablets, for oral use Initial U.S. Approval: 1997
0024-5851-902024-08-20These highlights do not include all the information needed to use AVAPRO safely and effectively. See full prescribing information for AVAPRO. AVAPRO ® (irbesartan) tablets, for oral use Initial U.S. Approval: 1997
0024-5851-902024-08-20These highlights do not include all the information needed to use AVAPRO safely and effectively. See full prescribing information for AVAPRO. AVAPRO ® (irbesartan) tablets, for oral use Initial U.S. Approval: 1997
0024-5851-302024-07-30These highlights do not include all the information needed to use AVAPRO safely and effectively. See full prescribing information for AVAPRO. AVAPRO ® (irbesartan) tablets, for oral use Initial U.S. Approval: 1997
0024-5851-302024-07-30These highlights do not include all the information needed to use AVAPRO safely and effectively. See full prescribing information for AVAPRO. AVAPRO ® (irbesartan) tablets, for oral use Initial U.S. Approval: 1997
0024-5851-302024-07-30These highlights do not include all the information needed to use AVAPRO safely and effectively. See full prescribing information for AVAPRO. AVAPRO ® (irbesartan) tablets, for oral use Initial U.S. Approval: 1997
0024-5851-902024-07-30These highlights do not include all the information needed to use AVAPRO safely and effectively. See full prescribing information for AVAPRO. AVAPRO ® (irbesartan) tablets, for oral use Initial U.S. Approval: 1997
0024-5851-902024-07-30These highlights do not include all the information needed to use AVAPRO safely and effectively. See full prescribing information for AVAPRO. AVAPRO ® (irbesartan) tablets, for oral use Initial U.S. Approval: 1997
0024-5851-902024-07-30These highlights do not include all the information needed to use AVAPRO safely and effectively. See full prescribing information for AVAPRO. AVAPRO ® (irbesartan) tablets, for oral use Initial U.S. Approval: 1997
0024-5851-302024-01-30These highlights do not include all the information needed to use AVAPRO safely and effectively. See full prescribing information for AVAPRO. AVAPRO ® (irbesartan) tablets, for oral use Initial U.S. Approval: 1997
0024-5851-302024-01-30These highlights do not include all the information needed to use AVAPRO safely and effectively. See full prescribing information for AVAPRO. AVAPRO ® (irbesartan) tablets, for oral use Initial U.S. Approval: 1997
0024-5851-302024-01-30These highlights do not include all the information needed to use AVAPRO safely and effectively. See full prescribing information for AVAPRO. AVAPRO ® (irbesartan) tablets, for oral use Initial U.S. Approval: 1997
0024-5851-902024-01-30These highlights do not include all the information needed to use AVAPRO safely and effectively. See full prescribing information for AVAPRO. AVAPRO ® (irbesartan) tablets, for oral use Initial U.S. Approval: 1997
0024-5851-902024-01-30These highlights do not include all the information needed to use AVAPRO safely and effectively. See full prescribing information for AVAPRO. AVAPRO ® (irbesartan) tablets, for oral use Initial U.S. Approval: 1997
0024-5851-902024-01-30These highlights do not include all the information needed to use AVAPRO safely and effectively. See full prescribing information for AVAPRO. AVAPRO ® (irbesartan) tablets, for oral use Initial U.S. Approval: 1997

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
0024-5851-30Avapro30 in 1 BOTTLETABLET, FILM COATED3021
0024-5851-90Avapro90 in 1 BOTTLETABLET, FILM COATED9021

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0024-5851-30EA - Each0024-585113047d17-4d3c-4593-90d0-c2e4c5dd186112013-03-03
0024-5851-90EA - Each0024-5851da7f2018-3464-415d-8578-9a7d56000b1412013-03-03

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIIDailyMed labelSPL versionUploaded
irbesartanACTIVE INGREDIENTJ0E2756Z7NAVAPRO (IRBESARTAN) TABLET [SANOFI-AVENTIS U.S. LLC]4
irbesartanACTIVE MOIETYJ0E2756Z7NAVAPRO (IRBESARTAN) TABLET [SANOFI-AVENTIS U.S. LLC]4
cellulose, microcrystallineINACTIVE INGREDIENTOP1R32D61UAVAPRO (IRBESARTAN) TABLET [SANOFI-AVENTIS U.S. LLC]4
croscarmellose sodiumINACTIVE INGREDIENTM28OL1HH48AVAPRO (IRBESARTAN) TABLET [SANOFI-AVENTIS U.S. LLC]4
hypromellosesINACTIVE INGREDIENT3NXW29V3WOAVAPRO (IRBESARTAN) TABLET [SANOFI-AVENTIS U.S. LLC]4
lactose monohydrateINACTIVE INGREDIENTEWQ57Q8I5XAVAPRO (IRBESARTAN) TABLET [SANOFI-AVENTIS U.S. LLC]4
magnesium stearateINACTIVE INGREDIENT70097M6I30AVAPRO (IRBESARTAN) TABLET [SANOFI-AVENTIS U.S. LLC]4
polyethylene glycol 3000INACTIVE INGREDIENTSA1B764746AVAPRO (IRBESARTAN) TABLET [SANOFI-AVENTIS U.S. LLC]4
silicon dioxideINACTIVE INGREDIENTETJ7Z6XBU4AVAPRO (IRBESARTAN) TABLET [SANOFI-AVENTIS U.S. LLC]4
titanium dioxideINACTIVE INGREDIENT15FIX9V2JPAVAPRO (IRBESARTAN) TABLET [SANOFI-AVENTIS U.S. LLC]4
irbesartanACTIVE INGREDIENTJ0E2756Z7NAVAPRO (IRBESARTAN) TABLET [LAKE ERIE MEDICAL DBA QUALITY CARE PRODUCTS LLC]1
irbesartanACTIVE MOIETYJ0E2756Z7NAVAPRO (IRBESARTAN) TABLET [LAKE ERIE MEDICAL DBA QUALITY CARE PRODUCTS LLC]1
cellulose, microcrystallineINACTIVE INGREDIENTOP1R32D61UAVAPRO (IRBESARTAN) TABLET [LAKE ERIE MEDICAL DBA QUALITY CARE PRODUCTS LLC]1
croscarmellose sodiumINACTIVE INGREDIENTM28OL1HH48AVAPRO (IRBESARTAN) TABLET [LAKE ERIE MEDICAL DBA QUALITY CARE PRODUCTS LLC]1
hypromellosesINACTIVE INGREDIENT3NXW29V3WOAVAPRO (IRBESARTAN) TABLET [LAKE ERIE MEDICAL DBA QUALITY CARE PRODUCTS LLC]1
lactose monohydrateINACTIVE INGREDIENTEWQ57Q8I5XAVAPRO (IRBESARTAN) TABLET [LAKE ERIE MEDICAL DBA QUALITY CARE PRODUCTS LLC]1
magnesium stearateINACTIVE INGREDIENT70097M6I30AVAPRO (IRBESARTAN) TABLET [LAKE ERIE MEDICAL DBA QUALITY CARE PRODUCTS LLC]1
polyethylene glycol 3000INACTIVE INGREDIENTSA1B764746AVAPRO (IRBESARTAN) TABLET [LAKE ERIE MEDICAL DBA QUALITY CARE PRODUCTS LLC]1
silicon dioxideINACTIVE INGREDIENTETJ7Z6XBU4AVAPRO (IRBESARTAN) TABLET [LAKE ERIE MEDICAL DBA QUALITY CARE PRODUCTS LLC]1
titanium dioxideINACTIVE INGREDIENT15FIX9V2JPAVAPRO (IRBESARTAN) TABLET [LAKE ERIE MEDICAL DBA QUALITY CARE PRODUCTS LLC]1

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
0024-5851AVAPRO (IRBESARTAN) TABLET, FILM COATED [SANOFI-AVENTIS U.S. LLC]18Current NDC, Legacy NDC, 2 package rows20250515_7885b2a8-be4e-48ab-8113-4e6ab791eb98.zip

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
AvaproIRBESARTANSanofi-Aventis U.S. LLC7885b2a8-be4e-48ab-8113-4e6ab791eb982026-02-19Boxed warning, Warnings, Adverse reactionsExact identifier
application applno (NDA): 020757
application number: NDA020757
ndc (product): 0024-5851

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYDailyMedSPL version
153666Avapro 150 MG Oral TabletPSN7885b2a8-be4e-48ab-8113-4e6ab791eb9821
153667Avapro 300 MG Oral TabletPSN7885b2a8-be4e-48ab-8113-4e6ab791eb9821
200095irbesartan 150 MG Oral TabletPSN7885b2a8-be4e-48ab-8113-4e6ab791eb9821
200096irbesartan 300 MG Oral TabletPSN7885b2a8-be4e-48ab-8113-4e6ab791eb9821
153666irbesartan 150 MG Oral Tablet [Avapro]SBD7885b2a8-be4e-48ab-8113-4e6ab791eb9821
153667irbesartan 300 MG Oral Tablet [Avapro]SBD7885b2a8-be4e-48ab-8113-4e6ab791eb9821
200095irbesartan 150 MG Oral TabletSCD7885b2a8-be4e-48ab-8113-4e6ab791eb9821
200096irbesartan 300 MG Oral TabletSCD7885b2a8-be4e-48ab-8113-4e6ab791eb9821
153666Avapro 150 MG Oral TabletSY7885b2a8-be4e-48ab-8113-4e6ab791eb9821
153667Avapro 300 MG Oral TabletSY7885b2a8-be4e-48ab-8113-4e6ab791eb9821

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionMarketing startMarketing endSampleExclude flagStatus
0024-5851-300002458513030 TABLET, FILM COATED in 1 BOTTLE (0024-5851-30) 2013-01-010000-00-00NoNoCurrent
0024-5851-900002458519090 in 1 BOTTLEHistorical